The role of enzalutamide in the treatment of prostate cancer from the perspective of Polish oncologists Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstrakt
For several years, prostate cancer has remained the most common malignancy in male patients in Poland. A large number of patients combined with rising costs of therapy translate into a significant socio-economic burden. In a clinical oncologist’s practice, we usually deal with patients with advanced prostate cancer. Taking into account the poorer prognosis in advanced disease, development of new therapeutic options as well we their adequate selection is of paramount importance. Enzalutamide is one of the second-generation androgen axis inhibitors, which has the ability to overcome resistance to androgen deprivation therapy by inhibiting the androgen-DNA signalling on several levels. Its efficacy and safety had been proven in numerous phase II and phase III clinical studies and it has been registered by regulatory authorities in the United States and European Union in the treatment of mCRPC, mCSPC and nmCRPC. In this article selected issues related to the treatment of prostate cancer are discussed, with particular emphasis on the role of enzalutamide (including its mechanism of action, indications, efficacy and safety).
Pobrania
##plugins.generic.paperbuzz.metrics##
##plugins.themes.bootstrap3.article.details##
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
2. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015; 314(1): 80-2. http://doi.org/10.1001/jama.2015.6036.
3. Fowler FJ, Barry MJ, Walker-Corkery B et al. The impact of a suspicious prostate biopsy on patients’ psychological, socio-behavioral, and medical care outcomes. J Gen Intern Med. 2006; 21(7): 715-21. http://doi.org/10.1111/j.1525-1497.2006.00464.x.
4. Didkowska J, Wojciechowska U, Olasek P et al. Nowotwory złośliwe w Polsce w 2019 roku .
5. Ellinger J, Alajati A, Kubatka P et al. Prostate cancer treatment costs increase more rapidly than for any other cancer – how to reverse the trend? EPMA J. 2022; 13(1): 1-7. http://doi.org/10.1007/s13167-022-00276-3.
6. Hernández S, Font-Tello A, Juanpere N et al. Concurrent TMPRSS2-ERG and SLC45A3 ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset. Prostate. 2016; 76(9): 854-65. http://doi.org/10.1002/pros.23176.
7. Swami U, McFarland TR, Nussenzveig R et al. Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends Cancer. 2020; 6(8): 702-15. http://doi.org/10.1016/j.trecan.2020.04.010.
8. Armstrong AJ, Azad AA, Iguchi T et al. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022; 40(15): 1616-22. http://doi.org/10.1200/JCO.22.00193.
9. Sternberg CN, Fizazi K, Saad F et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 382(23): 2197-206. http://doi.org/10.1056/NEJMoa2003892.
10. Armstrong AJ, Lin P, Tombal B et al. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol. 2020; 78(3): 347-57. http://doi.org/10.1016/j.eururo.2020.04.061.
11. Scher HI, Fizazi K, Saad F et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med. 2012; 367(13): 1187-97. http://doi.org/10.1056/NEJMoa1207506.
12. Penson DF, Armstrong AJ, Concepcion R et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol. 2016; 34(18): 2098-106. http://doi.org/10.1200/JCO.2015.64.9285.
13. Shore ND, Chowdhury S, Villers A et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016; 17(2): 153-63. http://doi.org/10.1016/S1470-2045(15)00518-5.
14. Schalken J, Fitzpatrick JM. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int. 2016; 117(2): 215-25. http://doi.org/10.1111/bju.13123.
15. Astellas Pharma Europe B.V. Charakterystka produktu leczniczego Xtandi. Xtandi – summary of product characteristics. Accessed May 9, 2022.
16. Del Re M, Fogli S, Derosa L et al. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treat Rev. 2017; 55: 71-82. http://doi.org/10.1016/j.ctrv.2017.03.001.
17. Van Leeuwen MT, Luu S, Gurney H et al. Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews. JNCI Cancer Spectr. 2020; 4(6): pkaa076. http://doi.org/10.1093/jncics/pkaa076.